Volume 136, Issue 5, Pages 1618-1628.e2 (May 2009) Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy  Thierry Poynard, Massimo Colombo, Jordi Bruix, Eugene Schiff, Ruben Terg, Steven Flamm, Ricardo Moreno-Otero, Flair Carrilho, Warren Schmidt, Thomas Berg, Thomas McGarrity, E. Jenny Heathcote, Fernando Gonçales, Moises Diago, Antonio Craxi, Marcelo Silva, Pierre Bedossa, Pabak Mukhopadhyay, Louis Griffel, Margaret Burroughs, Clifford Brass, Janice Albrecht  Gastroenterology  Volume 136, Issue 5, Pages 1618-1628.e2 (May 2009) DOI: 10.1053/j.gastro.2009.01.039 Copyright © 2009 AGA Institute Terms and Conditions

Figure 1 Patient flow and EPIC3 study design. HCV, hepatitis C virus; GCP, good clinical practice. *Data needed to calculate a log change at week 12 were missing for 184 patients. Of these patients, 175 continued participation in the retreatment study, and 9 either entered one of the maintenance protocols or discontinued. †Continued in the protocol at the discretion of the investigator. ‡All considered treatment failures. Gastroenterology 2009 136, 1618-1628.e2DOI: (10.1053/j.gastro.2009.01.039) Copyright © 2009 AGA Institute Terms and Conditions

Figure 2 Sustained virologic response rates by METAVIR score overall and among patients with undetectable HCV-RNA at treatment week 12. SVR, sustained virologic response. aData missing for 2 patients; P < .0001 to each other based on Mantel–Haenszel χ2 test. bData missing for 1 patient; P = .0004 to each other based on Mantel–Haenszel χ2 test conducted on the group that was negative at treatment week 12. Gastroenterology 2009 136, 1618-1628.e2DOI: (10.1053/j.gastro.2009.01.039) Copyright © 2009 AGA Institute Terms and Conditions